These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 16001992)
1. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. O'Shaughnessy JA; Clark RS; Blum JL; Mennel RG; Snyder D; Ye Z; Liepa AM; Melemed AS; Yardley DA Clin Breast Cancer; 2005 Jun; 6(2):143-9. PubMed ID: 16001992 [TBL] [Abstract][Full Text] [Related]
2. Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study. Llombart-Cussac A; Theodoulou M; Rowland K; Clark RS; Nakamura T; Carrasco E; Cruciani G Clin Breast Cancer; 2006 Dec; 7(5):380-5. PubMed ID: 17239262 [TBL] [Abstract][Full Text] [Related]
3. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881 [TBL] [Abstract][Full Text] [Related]
5. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830 [TBL] [Abstract][Full Text] [Related]
6. A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Estévez LG; Batista N; Sánchez-Rovira P; Velasco A; Provencio M; León A; Dómine M; Cruz J; Rodríguez M Clin Breast Cancer; 2008 Apr; 8(2):149-54. PubMed ID: 18621611 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644 [TBL] [Abstract][Full Text] [Related]
8. A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer. Martin M; Blasinska-Morawiec M; Salas JF; Falcon S; Rolski J; Ferrari BL; Gulyas S; Liu Y; Benhadji KA Clin Breast Cancer; 2009 Aug; 9(3):155-60. PubMed ID: 19661038 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. Sweeney CJ; Roth BJ; Kabbinavar FF; Vaughn DJ; Arning M; Curiel RE; Obasaju CK; Wang Y; Nicol SJ; Kaufman DS J Clin Oncol; 2006 Jul; 24(21):3451-7. PubMed ID: 16849761 [TBL] [Abstract][Full Text] [Related]
10. A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma. Duffaud F; Egerer G; Ferrari S; Rassam H; Boecker U; Bui-Nguyen B Eur J Cancer; 2012 Mar; 48(4):564-70. PubMed ID: 22243773 [TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Llombart-Cussac A; Martin M; Harbeck N; Anghel RM; Eniu AE; Verrill MW; Neven P; De Grève J; Melemed AS; Clark R; Simms L; Kaiser CJ; Ma D Clin Cancer Res; 2007 Jun; 13(12):3652-9. PubMed ID: 17575230 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. Perez EA; Lerzo G; Pivot X; Thomas E; Vahdat L; Bosserman L; Viens P; Cai C; Mullaney B; Peck R; Hortobagyi GN J Clin Oncol; 2007 Aug; 25(23):3407-14. PubMed ID: 17606974 [TBL] [Abstract][Full Text] [Related]
13. Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer. Wang HQ; Qian ZZ; Liu XM; Zhang HL; Li LF; Qiu LH; Hou Y; Zhou SY; Hao XS; Xie CH Chin Med J (Engl); 2010 Nov; 123(22):3212-6. PubMed ID: 21163117 [TBL] [Abstract][Full Text] [Related]
14. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632 [TBL] [Abstract][Full Text] [Related]
15. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Spielmann M; Martin M; Namer M; duBois A; Unger C; Dodwell DJ Clin Breast Cancer; 2001 Apr; 2(1):47-51. PubMed ID: 11899382 [TBL] [Abstract][Full Text] [Related]
16. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer. Garin A; Manikhas A; Biakhov M; Chezhin M; Ivanchenko T; Krejcy K; Karaseva V; Tjulandin S Breast Cancer Res Treat; 2008 Jul; 110(2):309-15. PubMed ID: 17851759 [TBL] [Abstract][Full Text] [Related]